Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BATTLE: Motixafortide and Atezolizumab for AML Maintenance
NCT03154827Phase 2Terminated
- Sponsor
- BioLineRx Ltd.
- Start
- Jan 2018
- Primary completion
- Apr 2020
- Modality
- Peptides
- Countries
- 6
01
Overview
Phase 2, open-label trial of motixafortide in acute myeloid leukemia (AML), sponsored by BioLineRx Ltd. Primary endpoints: Relapse Free Survival at 5 years and Safety and Tolerability at 2 years. Started Jan 2018; status: terminated.
02
Drugs
motixafortide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03154827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03154827.